Clinical Trials · NCT01060059
Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 888
- Start date
- Apr 2010
- Locations
- 50 sites, Italy
- Primary endpoint
- Percentage of Patients Who Achieved Glycemic Target of HbA1c ≤ 7.0% With Minimal Weight Gain (≤ 1 Kg) at Month 12.